|Bid||64.50 x 400|
|Ask||64.59 x 2000|
|Day's Range||64.31 - 64.75|
|52 Week Range||63.88 - 88.85|
|PE Ratio (TTM)||6.82|
|Dividend & Yield||2.08 (3.22%)|
|1y Target Est||N/A|
The Financial Women of San Francisco selected Gilead Sciences Chief Financial Officer Robin Washington as its 2017 Financial Woman of the Year. Washington was also recognized this week as the recipient of the lifetime achievement award at the “2017 Bay Area CFO of the Year Awards,” a program conducted by Larkin Street Youth Services in partnership with the Business Times. In accepting her award this week, it was clear that Washington spent a good portion of her career staying one step ahead of Oracle’s M&A department.
In 2016, Gilead Sciences’ (GILD) Truvada generated revenues of around $3.1 billion, reflecting ~3% year-over-year growth.
Gilead Sciences’ (GILD) HCV franchise was the company's highest revenue-generating division back in 2015.